{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:01:34Z","timestamp":1792512094467,"version":"4.5.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Use of the proteasome inhibitor carfilzomib has become a standard of care in patients with relapsed\/refractory multiple myeloma. An association between carfilzomib and cardiovascular adverse events has been well documented, but this had not been investigated in a racially diverse population. Black patients in particular are underrepresented in the reported outcomes of treatment with carfilzomib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The purpose of this study was to identify risk factors for carfilzomib-associated cardiovascular events in a diverse, single-center population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective review of 161 patients with multiple myeloma treated with carfilzomib between 2011 and 2020 at the University of Maryland Medical Center. Over half (86) were Black patients, with the remainder (75) being White patients. We did a multivariate analysis to determine risk factors for developing cardiovascular events during treatment with carfilzomib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no statistically significant association with cardiotoxicity and race, gender, or age at first dose of carfilzomib. In multivariable analysis, patients with history of hypertension had a higher risk of cardiotoxicity [adjusted odds ratio (OR): 2.5; 95% CI: 1.1\u20135.9;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03] as did those with a history of smoking [OR: 2.8; 95% CI: 1.3\u20136.4;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Here we report the largest cohort of Black patients treated with carfilzomib as yet reported. The results of this single center retrospective study show history of hypertension and smoking are associated with carfilzomib associated cardiotoxicity in a diverse patient population. There is a need for well-designed prospective studies enrolling a diverse population to investigate potential interventions to prevent carfilzomib-associated cardiotoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2023.1129943","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:36:47Z","timestamp":1686184607000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Hypertension, smoking, and preexistence of multiple cardiac risk factors correlate with carfilzomib-induced cardiovascular adverse events in a racially diverse population"],"prefix":"10.3389","volume":"10","author":[{"given":"Stacey","family":"Doran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Mysore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ebrahim","family":"Kassaian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Kotloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farin","family":"Kamangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Emadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jummai","family":"Apata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"B1","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3322\/caac.21555","article-title":"Cancer statistics for blacks, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1080\/10428194.2021.1953013","article-title":"Health disparities experienced by black and hispanic Americans with multiple myeloma in the United States: a population-based study","volume":"62","author":"Al Hadidi","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B4","doi-asserted-by":"publisher","first-page":"20406207211019612","DOI":"10.1177\/20406207211019612","article-title":"The role of carfilzomib in relapsed\/refractory multiple myeloma","volume":"12","author":"Yee","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"ASPIRE investigators. Carfilzomib, lenalidomide,and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"ENDEAVOR Investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiplemyeloma (ENDEAVOR):a randomised, phase 3, open-label, multicentrestudy","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2016.176","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)","volume":"31","author":"H\u00e1jek","year":"2017","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3389\/fcvm.2021.645678","article-title":"Effects of carfilzomib therapy on left ventricular function in multiple myeloma patients","volume":"8","author":"Mingrone","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12012-016-9378-7","article-title":"Molecular mechanism of the cardiotoxicity of the proteasomal targeted drugs bortezomib and carfilzomib","volume":"17","author":"Hasinoff","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European myeloma network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/bloodadvances.2021005482","article-title":"Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials","volume":"6","author":"Kanapuru","year":"2022","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"B15","volume-title":"Stata statistical software: Release 14","year":"2015"},{"key":"B16","doi-asserted-by":"publisher","first-page":"740796","DOI":"10.3389\/fonc.2021.740796","article-title":"Carfilzomib: a promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma","volume":"11","author":"Jayaweera","year":"2021","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"101536","DOI":"10.1016\/j.cpcardiol.2022.101536","article-title":"Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy","volume":"48","author":"Zheng","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","article-title":"Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study","volume":"12","author":"Dong","year":"2022","journal-title":"Blood Cancer J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1016\/j.jacc.2021.06.017","article-title":"Race, ethnicity, hypertension, and heart disease","volume":"78","author":"Ogunniyi","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B20","year":""}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1129943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:36:50Z","timestamp":1686184610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1129943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":20,"alternative-id":["10.3389\/fcvm.2023.1129943"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1129943","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"article-number":"1129943"}}